CLEC5A and pancreatic adenocarcinoma: Moreover, the expression of CLEC5A was also negatively associated with the survival of patients with LIHC, LUAD, and PAAD in GSE39582, GSE13213, and GSE57495, respectively (Supplementary Figure S1).